Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma.

Literature DB >> 27110676

Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma.

Anurag Mehta¹, Arjun Gupta, Franck Hannallah, Thomas Koshy, Sharon Reimold.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2016 PMID： 27110676 DOI： 10.1097/CMR.0000000000000251

Source DB: PubMed Journal: Melanoma Res ISSN： 0960-8931 Impact factor: 3.599

Keyword Cloud
Cited

× No keyword cloud information.

14 in total

Review 1. Biological agents in gastrointestinal cancers: adverse effects and their management.

Authors: Nivedita Arora; Arjun Gupta; Preet Paul Singh
Journal: J Gastrointest Oncol Date: 2017-06

Review 2. [The pathology of adverse events with immune checkpoint inhibitors].

Authors: V H Koelzer; K Glatz; L Bubendorf; A Weber; A Gaspert; G Cathomas; A Lugli; A Zippelius; W Kempf; K D Mertz
Journal: Pathologe Date: 2017-05 Impact factor: 1.011

3. Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab.

Authors: Alexandre Reuben; Mariana Petaccia de Macedo; Jennifer McQuade; Aron Joon; Zhiyong Ren; Tiffany Calderone; Brandy Conner; Khalida Wani; Zachary A Cooper; Hussein Tawbi; Michael T Tetzlaff; Robert F Padera; Jean-Bernard Durand; Alexander J Lazar; Jennifer A Wargo; Michael A Davies
Journal: Oncoimmunology Date: 2017-08-08 Impact factor: 8.110

4. Nivolumab-induced myocarditis complicated by complete atrioventricular block in a patient with metastatic non-small cell lung cancer.

Authors: Jin Lin Tan; Augustine Nyasha Mugwagwa; Luke Cieslik; Rohit Joshi
Journal: BMJ Case Rep Date: 2019-07-11

Review 5. PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism.

Authors: Hao Dong; Yihang Qi; Xiangyi Kong; Zhongzhao Wang; Yi Fang; Jing Wang
Journal: Front Pharmacol Date: 2022-04-19 Impact factor: 5.988

Review 10. Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases.

Authors: Emma Matzen; Lars Erik Bartels; Brian Løgstrup; Stine Horskær; Christina Stilling; Frede Donskov
Journal: Cardiooncology Date: 2021-08-09

Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma.

Review 1. Biological agents in gastrointestinal cancers: adverse effects and their management.

Review 2. [The pathology of adverse events with immune checkpoint inhibitors].

3. Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab.

4. Nivolumab-induced myocarditis complicated by complete atrioventricular block in a patient with metastatic non-small cell lung cancer.

Review 5. PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism.

Review 6. T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword.

7. Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action.

Review 8. Combination of CTLA-4 and PD-1 blockers for treatment of cancer.

Review 9. An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors.

Review 10. Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases.